Zai Capex To Depreciation vs Roe Analysis
ZLAB Stock | USD 27.73 1.18 4.08% |
Zai Lab financial indicator trend analysis is more than just analyzing Zai Lab current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zai Lab is a good investment. Please check the relationship between Zai Lab Capex To Depreciation and its Roe accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.
Capex To Depreciation vs Roe
Capex To Depreciation vs Roe Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zai Lab Capex To Depreciation account and Roe. At this time, the significance of the direction appears to have very week relationship.
The correlation between Zai Lab's Capex To Depreciation and Roe is 0.28. Overlapping area represents the amount of variation of Capex To Depreciation that can explain the historical movement of Roe in the same time period over historical financial statements of Zai Lab, assuming nothing else is changed. The correlation between historical values of Zai Lab's Capex To Depreciation and Roe is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Depreciation of Zai Lab are associated (or correlated) with its Roe. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Roe has no effect on the direction of Capex To Depreciation i.e., Zai Lab's Capex To Depreciation and Roe go up and down completely randomly.
Correlation Coefficient | 0.28 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Roe
Most indicators from Zai Lab's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zai Lab current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.At present, Zai Lab's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 1.49, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.4M | 14.6M | 16.8M | 17.6M | Depreciation And Amortization | 12.6M | 17.7M | 9.0M | 6.7M |
Zai Lab fundamental ratios Correlations
Click cells to compare fundamentals
Zai Lab Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zai Lab fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 355.2M | 1.3B | 1.6B | 1.2B | 1.0B | 754.6M | |
Other Current Liab | 10.3M | 24.0M | 46.1M | 45.5M | 58.9M | 61.8M | |
Total Current Liabilities | 46.6M | 98.0M | 192.9M | 139.8M | 203.1M | 213.2M | |
Total Stockholder Equity | 294.7M | 1.2B | 1.4B | 1.0B | 796.1M | 623.6M | |
Other Liab | 2.9M | 16.9M | 27.5M | 21.4M | 24.6M | 25.8M | |
Net Tangible Assets | 285.9M | 1.2B | 1.4B | 1.0B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 36.9M | 47.1M | 58.3M | 78.8M | 68.7M | 39.8M | |
Net Debt | (54.2M) | (423.5M) | (948.6M) | (988.1M) | (775M) | (736.3M) | |
Retained Earnings | (444.7M) | (713.6M) | (1.4B) | (1.9B) | (2.2B) | (2.1B) | |
Accounts Payable | 22.7M | 62.6M | 126.2M | 66.0M | 113.0M | 118.6M | |
Cash | 75.9M | 442.1M | 964.1M | 1.0B | 790.2M | 448.6M | |
Non Current Assets Total | 62.7M | 81.6M | 109.1M | 95.8M | 96.7M | 61.5M | |
Cash And Short Term Investments | 275.9M | 1.2B | 1.4B | 1.0B | 806.5M | 644.9M | |
Common Stock Total Equity | 3.0K | 3.5K | 4K | 5K | 5.8K | 3.0K | |
Common Stock Shares Outstanding | 87.8M | 77.7M | 93.0M | 95.8M | 96.6M | 76.3M | |
Liabilities And Stockholders Equity | 355.2M | 1.3B | 1.6B | 1.2B | 1.0B | 754.6M | |
Non Current Liabilities Total | 13.9M | 30.3M | 37.1M | 34.7M | 37.1M | 28.5M | |
Other Current Assets | 6.7M | 10.9M | 18.0M | 35.7M | 23.0M | 12.4M | |
Other Stockholder Equity | 734.7M | 1.9B | 2.8B | 2.9B | 3.0B | 1.5B | |
Total Liab | 60.5M | 128.3M | 230M | 174.5M | 240.2M | 131.0M | |
Total Current Assets | 292.5M | 1.2B | 1.5B | 1.1B | 939.6M | 693.0M | |
Accumulated Other Comprehensive Income | 4.6M | (14.5M) | (23.6M) | 25.7M | 37.6M | 39.5M | |
Intangible Assets | 8.8M | 9.4M | 9.7M | 8.4M | 16.5M | 17.3M | |
Common Stock | 3.5K | 4.1K | 5K | 6K | 6.9K | 4.2K | |
Property Plant Equipment | 36.4M | 46.9M | 57.3M | 77.4M | 89.0M | 93.4M | |
Non Currrent Assets Other | 510.2K | 743K | 803K | 2.2M | 2.3M | 2.4M | |
Other Assets | 15.1M | 110.1M | 26.5M | 3.6M | 4.1M | 3.9M | |
Long Term Investments | 2.4M | 1.3M | 15.6M | 6.4M | 9.2M | 5.5M | |
Current Deferred Revenue | 2.9M | 24.7M | 27.5M | 21.4M | 19.2M | 18.3M | |
Net Invested Capital | 301.1M | 1.2B | 1.4B | 1.0B | 796.1M | 814.3M | |
Net Working Capital | 245.8M | 1.1B | 1.3B | 984.5M | 736.5M | 759.3M | |
Short Term Debt | 10.8M | 10.4M | 11.9M | 7.1M | 14.2M | 13.5M | |
Short Long Term Debt Total | 21.8M | 18.6M | 15.5M | 20.4M | 15.2M | 17.4M | |
Net Receivables | 3.8M | 5.2M | 54.8M | 48.6M | 65.3M | 68.6M | |
Short Term Investments | 200M | 744.7M | 445M | 0.0 | 16.3M | 15.5M | |
Inventory | 6.0M | 13.1M | 19.0M | 31.6M | 44.8M | 47.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zai Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zai Lab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zai Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zai Lab Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. If investors know Zai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zai Lab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.80) | Revenue Per Share 3.647 | Quarterly Revenue Growth 0.477 | Return On Assets (0.21) | Return On Equity (0.35) |
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zai Lab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.